CS
KRTX

Credit Suisse’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Credit Suisse’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-39,291
Closed -$12.4M – 3058
2023
Q4 		$12.4M Buy
39,291
+8,460
+27% +$1.64M 0.01% 830
2023
Q3 		$5.21M Sell
30,831
-836
-3% -$157K 0.01% 1245
2023
Q2 		$6.87M Buy
31,667
+6,997
+28% +$1.5M 0.01% 1134
2023
Q1 		$4.48M Buy
24,670
+1,690
+7% +$323K ﹤0.01% 1396
2022
Q4 		$4.52M Sell
22,980
-201
-0.9% -$43.1K ﹤0.01% 1373
2022
Q3 		$5.21M Buy
23,181
+4,959
+27% +$1M 0.01% 1228
2022
Q2 		$2.31M Sell
18,222
-1,169
-6% -$134K ﹤0.01% 1811
2022
Q1 		$2.46M Buy
19,391
+3,202
+20% +$361K ﹤0.01% 1947
2021
Q4 		$2.12M Buy
16,189
+1,066
+7% +$138K ﹤0.01% 2741
2021
Q3 		$1.85M Buy
15,123
+3,467
+30% +$400K ﹤0.01% 2870
2021
Q2 		$1.33M Sell
11,656
-4,373
-27% -$511K ﹤0.01% 3167
2021
Q1 		$1.93M Sell
16,029
-6,507
-29% -$737K ﹤0.01% 2850
2020
Q4 		$2.29M Sell
22,536
-4,010
-15% -$372K ﹤0.01% 2719
2020
Q3 		$2.05M Sell
26,546
-5,069
-16% -$432K ﹤0.01% 2410
2020
Q2 		$3.52M Buy
+31,615
New +$2.75M ﹤0.01% 1940

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Credit Suisse's KRTX Position: Q1 2024 in Review

Credit Suisse sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 39,291 shares — an estimated $12.4M sold.

Credit Suisse first reported a position in KRTX in Q2 2020 and held it in 15 quarters. The position peaked at $12.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Credit Suisse reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Credit Suisse sold 39,291 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.4M.
  • Credit Suisse first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 15 quarters.
  • Credit Suisse's Karuna Therapeutics, Inc. Common Stock position peaked at $12.4M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.